C

Senior Director, Head of HEOR

Celcuity
Full-time
On-site
hybrid
Market Access
Our advice- run this job description AND your resume through AI- and see what the Employer's ATS will flag and evaluate if you are a match.
If you're aiming for a job like this, you need an edge.

Our JobsAI tool gives you that edgeโ€”by helping you upgrade your resume, analyze hiring managersโ€™ LinkedIn profiles, and prepare with a built-in interview coach.

Get a FREE trial and see for yourself!

๐Ÿ‘‰ Check out JobsAI

Senior Director, Head of HEOR

Location

Remote

Position Summary

Celcuity is seeking a research and customer-facing position who will report into the Vice President of Market Access. As a senior member of the Access Leadership Team, you will play a key role in helping shape strategy, identify best practices, and contribute to the development of a best-in-class HEOR team, focused on field-based collaborative research. This role will play a critical role in shaping how our therapies are perceived by payers, providers, and the broader healthcare ecosystem. The Senior Director will collaborate cross-functionally to develop and implement HEOR/RWE strategies that demonstrate the value of our innovation in advanced cancers โ€“ supporting access, adoption and long-term impact.

Responsibilities

  • Lead the design and implementation of integrated RWE and HEOR plans to support Celcuityโ€™s asset(s)
  • Identify evidence gaps and prioritize real-world studies to inform treatment patterns, disease burden, patient-reported outcomes, and unmet needs
  • Support the development of value-based narratives to articulate the clinical, economic, and societal impact of our therapies
  • Design and execute real-world studies (e.g. burden of illness, cost-effectiveness, comparative effectiveness)
  • Develop and maintain budget impact model/analysis, AMCP dossiers, and other evidence to support payer and account engagements
  • Publish and present findings at scientific conferences, in peer-reviewed journals, and medical meetings to build the evidence base for gedatolisib in studied/approved disease areas.
  • Partner with clinical development, regulatory and commercial teams to align on RWE/HEOR strategy and execution
  • Serve as a scientific and strategic expert internally and externally
  • Lead vendor selection and manage external research partners to ensure high-quality and timely study delivery
  • Ensure development of needed resources to support engagements with population-based decision makers
  • Ensure compliance with all applicable ethical, regulatory, and privacy standards
  • Contribute to overall Market access planning, launch readiness, and evidence strategy for upcoming milestones

Qualifications

  • Pharm D preferred
  • 10+ years of US Oncology Experience
  • 10+ credited publications
  • 10+ years of RWE/HEOR within the biopharma environment
  • 2+ years leadership experience
  • Combination of academic training and practical experience in scientific methods is required
  • Proven ability to translate complex evidence into compelling value messages for payers and providers
  • Demonstrated success in designing and leading real-world research to support regulatory and payer decision making
  • Success in influencing access and reimbursement strategies in the US market
  • Proven track record of publications and presentations in high-impact settings
  • Excellent leadership and cross-functional collaboration skills, with ability to influence and drive strategy across teams
  • Experience with patient-reported outcomes and value frameworks in chronic disease management

About Us

Celcuity is a clinical-stage, publicly traded biotechnology company seeking to extend the lives of cancer patients through the development of targeted therapies for the treatment of multiple solid tumor indications. The company was founded to develop a better way to treat the cellular drivers of tumor growth.

Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Gedatolisib phase 3 clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings. A Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going.

Celcuity is an equal-opportunity employer.

Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are market competitive. For this role, the anticipated base pay range is $ - $. The exact base pay offered for this role will depend on various factors, including but not limited to the candidateโ€™s geography, qualifications, skills, and experience.

The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401k match, PTO, and several paid holidays.

Notice to Recruiters/Staffing Agencies

Recruiters and staffing agencies should not contact Celcuity through this page. All recruitment vendors (search firms, recruitment agencies, and staffing companies) are prohibited from contacting our hiring manager(s), executive team members, or employees.

We require that all recruiters and staffing agencies have a fully executed, formal written agreement on file.

Celcuityโ€™s receipt or acceptance of an unsolicited resume submitted by a vendor organization to this website or employee does not constitute an actual or implied contract between Celcuity and such organization and will be considered unsolicited and Celcuity will not be responsible for related fees.